The tria popukuion Detailed methods have been described previously (Roberts et al., 1984 
women formed the control group. After 10 years, breast cancer mrtaty is 14-21% lower in the study group than in the controls dependig on the precise definiton of the end point. (UK Breast Cancer Detection Working Group, 1993) and their data include comparisons of the present study group with geographical controls. The control groups for the TEDBC and the Edinburgh trial are entirely distmct The first report of the Edinburg trial (Roberts et al., 1990) iied results for 7 years' folow-up for breast cancer mortality and 5 years' follow-up for breast cancer incidence. A reduction of 17% in breast canr mortality in the study group was observed at that time (relative risk = 0.83, 95% confidence interval 0.58-1.18). The results of 10 years of follow-up are now reported. In additon to the initial cohort of the trial, younger women (aged [45] [46] [47] [48] [49] 
Method
The tria popukuion Detailed methods have been described previously (Roberts et al., 1984 Alexander. Randomisation and screening The 87 practices were randomised to study or control status, which provided cluster randomisation for individual women who derived their status within the trial from that of their practice at entry. Women in the study group were offered screening, and those who attended (61.3%) underwent twoview mammography and clinical examination at their initial visit (prevalen screen). Further screening (incidence screens) used annual clinical examination for 6 years and included single-oblique view mammography in alternate years. Attendance rates fell with time and were just over 50% during the final (seventh) year of fieldwork (Roberts et al., 1990) .
For the majority of women who continued in screeimng each screen occurred within 1 year of the intended time -so that, for example, the screen in 'year 3' occurred between 2 and 3 years from survey entry; these women are described as having 'regular' screening. The NHS introduced service screening in Scotland in 1988 for women then aged [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] years. For practical and administive reasons this had to be introduced gradually and the Edinburgh programme was coordinated with the present trial in such a way that all women who were still in regular screening had their first invitation to service screening at (approximately) 3 years after their last (year 7) trial screen; this was during their tenth year of follow-up.
Follow-up
Apart from the collection of medical information and screening histories at the screening clinic, follow-up of women in the two arms of the trial has been identical (Roberts et al., 1984 (Roberts et al., , 1990 . For the field-work period of the trial (1978-88) local follow-up for both breast cancer incidence and total mortality were used as independent data sources alongside flagging. Since then, flagging has provided the primary, and for mortality data the only, source of follow-up. Scrutiny of counts of death notifications from flagging suggests that these data are virtually complete after a time lag of 6 months. Data for the present analysis were finalised in January 1993 so that ascertaiment of relevant deaths (occurring 1991 or earlier) could be ensured.
Whenever a death certifiate mentioned breast cancer as a cause of death for a woman who had not already been identified as a breast cancer case the trial staff sought confirmation of diagnosis. If this occurred before survey entry date the woman was ineligible for the trial.
Flagging for cancer incidence may be less reliable than flagging for mortality. Therefore the entire trial cohort was matched against the Scottish Cancer Registration Scheme database held centrally by the Information and Statistics Division (ISD) of the Scottish Health Services Common Services Agency. The cancer registration database is matched annually with the Scottish hospitals inpatient database. Linkage with the trial database used probability matching and included all notifications of cancer registed up to the end of 1991. These methods optimised ascetainment of breast cancer incidence in the trial population for the full 10 years of follow-up.
Analysis of breast cancer mortality
The primary end point for analysis is 'breast cancer mortality' and, in the initial report (Roberts et al., 1990) , this was defined to be mention of breast cancer on either part 1 or part 2 of the death certificate. We to potential bias and definition 1 has been taken as the principal definition of the end point.
As in the previous report, deaths occurring as results of non-epithelial cancers in the breast (e.g. sarcoma, lymphoma)
are not included in the anlysis.
Following the trial protocol (Roberts et al., 1984) , the main analysis has been of breast cancer mortality in the whole of the initial cohort for 10 years from survey entry. We also report the results of two subsidiary analyses focused on possible differential effects of screening women over and under 50 years of age. Firstly, breast cancer mortality over the 10 year period for the initial cohort has been analysed separately for the two age groups: 45-49 years and 50-64 years at survey entry. Secondly, we have included updates in the analysis of younger women; women entered during 1982-83 are followed-up for 8 years and later updates for 6 years (sine randomisation was in two groups by year at entry). The analyses to be conducted were decided in advance of data inspection.
For the statistical analysis mortality has been expressed as rates of breast cancer deaths per 10,000 woman-years at risk. Rates in study and control pract were compared and their ratio alculated. As before (Roberts et al., 1990 ), a modified logistic regrsion procedure incorporated adjustment for extrabinomial regression (Williams, 1982) so as to respect the cluster randomisation. All analyses were implemented in 'GLIM' and stratified by age at survey entry (45-49, 50-54, 55-59 and 60-64 years) . Where updates are included there has been further stratification by length of follow-up. Cumulative breast cancer mortality curves are expressed as rates per 10,000 women entering the study but are adjusted to take account of women-years at risk. The general practice 'clusters' have been claified into three groups by levels of a socioeconomic score (SEG) as in the previous report (Roberts et al., 1990) .
Analysis ofbreast cancer incidence Staging of disease follows standard UICC clinical staging (UICC, 4th edn, 1987) and stage 0 corresponds to carcinoma in sitwL for cases which are stage I-H pathological information is also provided.
Cancers det in women who had attended their last trial screen (i.e. seventh screen, 6-7 years from entry) but had not yet had a service screen are described as 'intervals'; cases arising in the period 36-42 months after the last trial screen and before invitation to the service screening are included as intervals. The proportional incidence of utterval cancers is the ratio of the incidence rate of these interval cancers to that observed in the control group (adjusting for the age distribution of the population at risk).
Cumulative incidence of cancers known to be advanced in the total trial population have been plotted by year of follow-up for two definitions of 'advanced': firstly, UICC stages III and IV and, secondly, that used by Tabar et al. (1985) . These figures are adjusted for wom}en-years at risk.
Reslts
The trial population is shown in Table I with women-years of follow-up. Of the study population 61.3% responded to the initial invitation to screening, but only 44.1% attended the seventh screen. The numbers of women known to be ineligible on account of pretrial breast cancer are also shown; prospective ascertainment is more complete for the study group and, to avoid consequential bias, these women have been retained in the calculations of women-years for the denominators. Breast Figure la .
Results for subgroup analyses using the principal end point definition are reported in Table III . These provide no evidence that a larger mortality reduction has been achieved in older women (i.e. those aged 50 years or more at trial entry). When the younger women were analysed separately (Table III and Figure lb ) the total numbers of breast cancer Table III were repeated for the other definitions of breast cancer death, the results were qualitatively similar. The mortality reduction for these women did not depend on whether the age at diagnosis exceeded 50 years.
Breast cancer incidence
Altogether, 489 breast cancers were diagnosed in the 10 year period in the study population (22.4/10,000 women-years) and 400 in the controls (20.0/10,000 women-years). The UICC stage distribution is more favourable for the study population than for the controls (Table IV) ; percentages of invasive cancers classified as stages III or IV are 17% and 32% respectively. Cumulative rates (Figure 2a) Figure  2b) show excesses in the study group for the first 7 years, but thereafter a divergence in favour of the study group is emerging.
The rates of interval cases in the 3 years after the trial screening ended (Table V) All-cause mortality and effect of socioeconomic status All-cause mortality in the total trial population was 103.9/ 10,000 women-years, which is similar to that expected in a cohort of Scottish women of this age. The rates in the study group were 15% lower than in the controls (relative risk = 0.85, 95% confidence interval 0.79-0.92). This difference cannot be attributed to breast cancer, which represented only 4.7% of all deaths. When the trial population was split into three groups by SEG of the general practice clusters, the rates were 84.9, 104.1 and 126.1 with the lowest rates in the highest SEG; the trend is statistically significant (P < 0.00001). More women in the study population were in the highest SEG group (percentages of women-years were 53% and 26% in the study and control groups respectively) and fewer were in the lowest SEG group (27% compared with 42%). Thus the differences in all-cause mortality can be (0) and control (+) groups over 10 years of follow-up: (a) UICC clinical staging III, IV; (b) advanced disease as defined by Tabar et al., 1985. These results based on 10 years of follow-up confirm our earlier findings (Roberts et al., 1990) . There is a reduction in breast cancer mortality of around 18% in the total study population. This is not statistically significant and the confidence intervals are wide so that, by themselves, the results are inconclusive. They should be interpreted in context and are consistent with the consensus (Wald et al., 1991) that mammographic screening reduces breast cancer mortality but by rather less than the 30% originally found in the HIP study (Shapiro et al., 1982) and later by the Swedish two-counties trial (Tabar et al., 1985) . Other trials in Sweden have achieved smaller reductions, and the recent Swedish overview (Nystrom et al., 1993) Group, 1993) ; these are statistically significant but rely on difficult adjustments using pretrial breast cancer standardised mortality ratios (SMRs) for the geographical regions.
A number of design or execution problems for the study have been discussed previously (Roberts et al., 1990) but should be noted here; these include the attendance rate, mammographic quality in the early years, loss of efficiency from cluster rather than individual randomisation and statistical power. All of these will have a conservative effect. Other potential sources of bias were, firstly, different use of adjuvant systemic therapy (Early Breast Cancer Trialists Collaborative Group, 1992) between the two groups and, secondly, differential errors of ascertainment of breast cancer deaths. We have demonstrated that the first does not apply and our methods of ascertainment avoid the latter.
Establishing whether death is attributable to breast cancer is difficult in a small number of cases. The review of a random sample of deaths with breast cancer underlined on the death certificate has confirmed previous findings: overestimation of breast cancer as a cause of death of around 6% (Brinkley et al., 1984 ; UK Breast Cancer Detection Working Group, 1991) . The review of case notes reveals that small errors have occurred in the classification of the remaining deaths of breast cancer patients, but these data are compatible with other recommendations (Brinkley et al., 1984) that analyses should use death certificate classifications of the underlying cause of death. Non-differential misclassification in the data will be a further source of conservative bias.
An unexpected consequence of the use of cluster sampling is the bias between the two arms of the trial, which is evidenced in the differences in all-cause mortality. This is in part explained by lower socioeconomic status in the control group (Alexander et al., 1989) . There is a body of evidence demonstrating that the direction of the association of socioeconomic status with breast cancer is opposite to that for all-cause mortality (Tomatis et al., 1990; Scottish Breast Screening Progamme, 1993 (Wald et al., 1991) . Our data do not indicate that this age range fared better than the younger women.
There is currently no consensus on the merits of screening younger women (Beral, 1993; Elwood et al., 1993; Fkltcher et al., 1993) . The principal difficulty is that no trial of traditional design has been conducted with sufficient statistical power to analyw this age group separately. In addition, most authors fail to distnguiish between the short and longer follow-up periods. For short follow-up periods (i.e. 7 years or less) all publishd trial results give point estimates of the relative risk which are either close to unity or exceed it (Shapiro et al., 1982; Miler et al., 1992; Nystrom et al., 1993) . This is supported by the Malmo trial (Andersson et al., 1988) and the only relevant case-control study (Verbeek et al., 1985) . For longer follow-up periods the HIP trial reported reductions in breast cancer mortality for younger women (first screened when 40-49 years) which was eventually of the same magnitude as that in older women (Shapiro et al., 1988) and, in one analysis (Chu et al., 1988) (Morrison et al., 1988 Tabar et al. (1985) and, in particular, to achieve major reductions in the frequency of nodal metastases amongst the smaller cancers (t<20 mm). Half of all invasive cancers in ever-screened women are poor prognosis compared with 33% in the Swedish two-counties trial (Tabar et al., 1985) . In both trials the percentages in the never-screened women (80% and 73% respectively) exceeded those in the controls, but the impact on the total study group is greater in Edinburgh on account of the lower attendance rate. The cumulative incidence of this poor-prognosis disease is not substantially reduced in the Edinburgh study group -although the results for the years [8] [9] [10] give preliminary indications that the curves may be diverging strongly. In the two-counties trial the changing incidence was reflected by the mortality curve (Tabar et al., 1985) , and subsequent analyses (Tabar et al., 1992) have demonstrated that it is strongly predictive of mortality. Much of the failure of our mortality reduction to increase between 7 and 10 years of follow-up is likely to be explained by delay in this aspect of performance. Although we have detected large numbers of in situ cancer, this is predicted to have less impact on mortality than reducing the rate of small node-positive cancers (Tabar et al., 1992) . One of the strengths of the present trial database is that high achievement in pathological classifictions of nodal status within one city has permitted an analysis which identifies the problem more clearly than is possible using tumour size alone (UK Breast Cancer Detection Working Group, 1993) .
When service screeing was introduced into Edinburgh we took the opportunity of designing a protocol which would enable us to report on the interval cancer rates over 3 years in regularly screened women; these should be predictive of eventual rates in the service programme with its 3 yearly schedule. The optimum interval between examinations is unknown; a randomised trial comparing 1 yearly intervals with 3 yearly ones is currently in progress (N. Day, personal communication) but will not report for several years. Meanwhile, the best method of evaluating the inter-screening interval is to compare the proportional incidence of interval cases across the period (Tabar et al., 1987) . The proportions we report are based on small numbers but exceed those for the two-counties trial in both the second (42% compared with 29%) and third (67% compared with 45%) year (Tabar et al., 1987) . This indicates, firstly, that the interval could be too long and should certainly not exceed 3 years -for the population or for individual women. Secondly, it may be further evidence that screening as practised during the trial lacked sensitivity for detecting biologically important cancers.
In conclusion, this trial has provided modest but important contributions to the overall scientific evaluation of mammographic sceening. These include further evidence that screening -at least for women over 50 years -can reduce mortality from breast cancer by around 20%. With current standards of mammography and higher attendance rates larger reductions may be achievable. The extension of results from scientific trials to routine health care can be problematic, but current reports from UK service screening are encouraging (Chamberlain et al., 1993; Scottish Breast Screening Programme, 1993) . Thr is a need to determine the best age for screening to commence. Since the benefits of screening take at least 4 years to emerge, the present service screening programme though targeted at women of 50 years and over will have little impact on mortality from the disease in women aged 50-54 years despite the fact that 20% of all deaths of British women in this age group are due to breast cancer (OPCS, 1989-93) .
Finally, two warning messages emerge from this study:
firstly, follow-up and recall facilities must ensure that minimal numbers of women wait for more than 3 years between their invitations to screening. Secondly, screening targets must focus on detection of cancers before nodal metastases develop rather than relying on favourable size. It follows that it is essential to the monitoring of the UK service screeing programme that histological evidence of node status is available on all cases arising in the target population. We also thank Dr Michael Ashley Millar and Dr Boyd Moir for help in coordinating the funding and Dr Helen Stewart for her assistance in the collection of recent data and classification of review causes of death. We acknowledge the assistance of the staff at the General Register Office, Scotland, the Lothian Health Board Primary Health Care Division and general practitioners in Edinburgh as well as our colleagues in the Screening Clinic and the University Departments of Public Health Science, Pathology and Surgery. Additional secretarial support was provided by the Leverhulme trust.
